A Phase 4, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Renal Protective Effect (UACR), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Ipragliflozin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Astellas Pharma Korea
- 22 Sep 2018 Planned End Date changed from 1 Feb 2019 to 1 Jan 2019.
- 22 Sep 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Jan 2019.
- 22 Sep 2018 Status changed from recruiting to active, no longer recruiting.